Two Novel ATP8B1 Mutations Involved in Progressive Familial Intrahepatic Cholestasis Type 1 That is Ameliorated by Rifampicin: A Case Report
Yan Huang,Enjing Luo,Min Li,Jing Yang,Jian He Gan,Weifeng Zhao
DOI: https://doi.org/10.1111/1751-2980.13078
2022-01-01
Journal of Digestive Diseases
Abstract:To the Editor, Progressive familial intrahepatic cholestasis (PFIC) is a group of inherited liver diseases characterized by defects in the transporters of the biliary epithelia. With the development of genetic technologies, at least six major types of PFIC have been identified and are found to be attributed to disease-causing genes (eg, ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, MYO5B). Autosomal recessive mutations of the ATP8B1 gene can cause progressive familial intrahepatic cholestasis type 1 (PFIC1), a severe form of hereditary cholestasis. If left untreated, PFIC1 may progress to liver fibrosis, cirrhosis and devastating end-stage liver failure, eventually requiring liver transplantation in some cases. The ATP8B1 gene is located on chromosome 18q21-22 and encodes the familial intrahepatic cholestasis 1 (FIC1) protein, a P-type ATPase in the P4 family that is involved in bile acid homeostasis and plays a critical role in bile secretion. When the function of FIC1 is impaired due to ATP8B1 gene mutation, bile acids can accumulate, thus injure the hepatocytes and lead to cholestasis in PFIC1. To date, the precise mechanisms by which FIC1 deficiency leads to the onset of cholestasis remain unclear. To our knowledge, there have been no evident results from clinical trials for identifying carriers. Thus, the genetic causes of PFIC1 and the carriers need to be identified for the early detection and prenatal diagnosis of PFIC1. Although the spectrum of disease-causing mutations of the ATP8B1 gene is expanding, such mutations have not yet been fully discovered. Currently available comprehensive treatment options for patients with PFIC1 include conservative management with medications, biliary bypass surgery, and liver transplantation. To date, genespecific therapy has not been applied in clinical practice for FIC1 deficiency in patients with PFIC1. Here we reported a male patient with PFIC1 and tried to identify the genetic causes of PFIC1 in a male patient. A 22-year-old man was admitted to our hospital due to progressive yellow discoloration of skin and sclera over a period of 2 months and pruritus that had lasted for 1 month. His serum liver biochemistry showed total bilirubin (TBIL) level of 667 μmol/L, direct bilirubin (DBIL) of 475 μmol/L, alanine aminotransferase (ALT) of 31 U/L, aspartate aminotransferase (AST) of 28 U/L, alkaline phosphatase